DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for motor neuron disease — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMotor neuron disease maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for motor neuron disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
superoxide dismutase 1 (SOD1) — SOD1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet udidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8CCX · 1.665 Å · ligand butane-1,4-dithiol (UDI). Experimental structure, not a prediction.
What the evidence adds up to
A 1974 paper proposed that the initial pathogenic event in motor neurone disease is a progressive inhibition of DNA-directed mRNA synthesis caused by slow condensation of chromatin, with all other pathological changes following as non-specific cell atrophy. This hypothesis has not been confirmed or translated into a treatment. A 2006 study mapped a novel autosomal recessive lower motor neurone disease with childhood onset to a 3.9 cM interval on chromosome 1p36 in a consanguineous African family; four of five affected patients had muscle weakness from age 3 that progressed to generalised tetraplegia in adulthood. The region contains 27 candidate genes, but no specific gene has been identified from this locus.
A 2014 review of investigational drugs for Huntington’s disease noted that selisistat and PBT-2 were among the few agents then considered potentially disease-modifying, but the review did not test these drugs in motor neurone disease and reported no data on their use in that population. A 2011 article stated plainly that there is no cure for motor neurone disease and that the disease cannot be prevented, though symptoms can be reduced. A 2010 quality standards framework for supportive management of motor neurone disease emphasised that multidisciplinary specialist care improves survival and quality of life, but offered no disease-modifying drug.
No drug from these abstracts has been shown to alter the course of motor neurone disease in a controlled trial. What is missing is a confirmed molecular target derived from the 1974 chromatin hypothesis, a validated gene from the 1p36 locus, and any trial that tests a disease-modifying agent specifically in motor neurone disease patients with appropriate stratification by genetic subtype or disease stage.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neurology Neurosurgery & Psychiatry · 1974 · 73 citations · open access
Motor neurone disease: the nature of the pathogenic mechanism
AbstractEvidence is presented which indicates that the initial site of action of the pathogen of motor neurone disease (MND) is the nucleus, and its prime effect is to cause the progressive inhibition of DNA directed mRNA synthesis by the slow condensation of chromatin from a metabolically active diffuse form to an inactive form. The other pathological changes observed follow as part of a nonspecific cell atrophy which leads eventually to dysfunction, death, and disappearance of cells.
A gene for an autosomal recessive lower motor neuron disease with childhood onset maps to 1p36
AbstractOBJECTIVE: To describe the clinical features of a novel variant of autosomal recessive lower motor neuron disease (LMND) with childhood onset and to map the disease-causing gene. METHODS: The authors performed a clinical study in a large consanguineous African family. After linkage exclusion to SMN1 and SOD1 loci, they performed a genome-wide linkage analysis to map the underlying genetic defect. RESULTS: This novel variant of LMND with childhood onset and autosomal recessive mode of inheritance is characterized by a progressive symmetric and generalized involvement of the musculature. Four of the five affected patients had muscle weakness since age 3, strongly worsening during childhood and leading to generalized tetraplegia in adulthood. Genetic analyses using homozygosity mapping strategy assigned this progressive generalized LMND locus to an interval of 3.9 cM (or 1.5 megabases) on chromosome 1p36, between loci D1S508 and D1S2633 (Z(max) = 3.79 at theta = 0.00 at locus D1S253). This region encloses 27 candidate genes. CONCLUSION: Genetic mapping of a novel rare phenotype of lower motor neuron disease opens the way toward the identification of a new gene involved in motor neuron degeneration, located in the 1p36 chromosomal region.
Expert Opinion on Investigational Drugs · 2014 · 4 citations
Investigational drugs for the management of Huntington’s disease: are we there yet?
AbstractINTRODUCTION: Huntington's disease is a hereditary neurodegenerative disease. It is designated as a rare disease in the US, which means there are < 200,000 patients in the country who suffer from it. The drugs that are currently used to treat this disease were not designed specifically for it but developed for other diseases. Presently, two classes of drugs are being developed; those that provide symptomatic relief and those that may modify course of the disease. AREAS COVERED: This review is focused on seven selected drugs currently in clinical testing and describes their progress. Five of the seven drugs that are reviewed here, can be categorized as 'symptomatic' drugs, and, selisistat and PBT-2 are amongst the ones that would qualify as 'disease modifying' drugs. EXPERT OPINION: The authors believe that the future treatment paradigm for this disease is best met by using a disease-modifying drug that can be administered together with symptomatic drugs. Towards that end, it is important for the industry to focus on disease-modifying drugs by targeting unique pathways and targets. Furthermore, they propose that neuroprotective drugs, that is, drugs that directly work by preserving neuronal health and function is an opportunity for such disease-modifying drugs.
British Journal of Healthcare Assistants · 2011 · 0 citations
Motor neurone disease: research, treatment and care
AbstractClinicians and researchers do not fully understand why motor neurone disease (MND) occurs, but they know how the body is affected. Unfortunately, this means that there is currently no cure for MND and the disease cannot be prevented, although the symptoms of the various forms of MND can be reduced. This article, the second in a series, outlines current treatments as well as potential future treatments that are currently undergoing clinical trial. It also looks at ways in which those with the condition can be assisted by support workers.
A QUALITY STANDARDS FRAMEWORK FOR THE USE OF ICT IN LEARNING – FIT LTD. EXPERIENCE FROM A EUROPEAN PROJECT
AbstractThe aim of supportive management of motor neuron disease is to improve survival, promote good quality of life and patient independence and autonomy whilst preparing for future progression and the end of life. Multidisciplinary specialist care aims to address the multifaceted and interacting biopsychosocial problems associated with motor neuron disease that leads to proven benefits in both survival and quality of life. This chapter will explore principles, structure and details of treatment options, and make recommendations for practice and for future research.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
